Drug news
IDX 184 (Idenix) in Phase II for Hepatitis C
Idenix Pharmaceuticals has reported positive data from both an interim analysis of a Phase II study of its drug candidate for Hepatitis C virus , IDX184. The company plans to begin a combination study of the IDX 184 and IDX 719, which has just completed a proof of concept study, by the end of the year.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.